Completed PHASE2 INTERVENTIONAL NCT00028860

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium

Sponsor: Tulane University Health Sciences Center

Conditions Bladder Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter

Interventions adjuvant therapy carboplatin filgrastim gemcitabine hydrochloride ifosfamide paclitaxel

Updated 5 times since 2017 Last updated: Jul 9, 2013 Started: Oct 31, 2001 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter and is currently completed. Tulane University Health Sciences Center leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tulane University Health Sciences Center

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Orleans, United States